09 Nov Blood-based biomarkers identify metastatic-castration-resistant-prostate-cancer patients who benefit from continuing enzalutamide beyond progression in combination with docetaxel in the PRESIDE trial

ID: 2513

Autores: Ruiz Vico, Maria (0); Ruiz-Vico, Maria (1,2,3); Wetterskog, Daniel (1); Orlando, Francesco (4); Thakali, Suparna (1); Wingate, Anna (1); Jayaram, Anuradha (1); Vaniuskas, Osvaldas  (1); Cremaschi, Paolo (1); Castellano-Gauna, Daniel (3); Astrom, Lennart (5); Matveev, Vsevolod  (6); Bracarda, Sergio (7); Esen, Adil (8); Feyerabend, Susan  (9); Senkus-Konefka, Elżbieta (10); López-Brea Piqueras, Marta (11); Gupta, Santosh  (12); Wenstrup, Rick (12); Boysen, Gunther (13); Martins, Karla (13); Iwata, Kenneth (14); Gourgioti, Georgia (13); Serikoff, Alexis (13); Tausis, Monika (13); Merseburger, Axel (15); Chowdhury, Simon (16); Demichelis, Francesca (4); Attard, Gerhardt  (1)

Temática: New frontiers in treatment/Precision medicine